Lipsomal Adriamycin
Executive Summary
Liposome Technology reports that preliminary results of international, 40-patient Phase I trial show reduction of side effects with improved patient tolerance compared to conventional formulation of Adriamycin. Liposome Technology is also developing a liposomal formulation of the antifungal amphotericin B.